Literature DB >> 11220101

[MRI-controlled percutaneous cryotherapy of liver metastases].

P Haage1, J Tacke.   

Abstract

The prognosis for patients with liver metastases depends on the therapeutic options regarding the treatment of the primary tumor, co-existing extrahepatic metastases and the extent and treatment possibilities of the hepatic metastases themselves. Numerous curative or palliative oncological therapeutic concepts have been introduced in case of non-resectable liver metastases to prolong survival while maintaining a highest possible quality of life. Cryotherapy, which can be performed percutaneously and under magnetic resonance guidance, is one of these manifold therapeutic modalities, combining the inherent advantages of MRI with minimal invasiveness. Excellent visualization of the frozen liver tissue, precise tumor ablation, as well as an almost painless intervention due to the analgetic effect of the ice are implicating percutaneous cryotherapy as an attractive alternative to other ablation techniques. First clinical results are promising. However, meticulous and extensive long-term evaluation on a broad clinical scale is required.

Entities:  

Mesh:

Year:  2001        PMID: 11220101     DOI: 10.1007/s001170050930

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  3 in total

1.  MRI-compatible manipulator with remote-center-of-motion control.

Authors:  Nobuhiko Hata; Junichi Tokuda; Shelley Hurwitz; Shigehiro Morikawa
Journal:  J Magn Reson Imaging       Date:  2008-05       Impact factor: 4.813

2.  [Cryoablation - back again?].

Authors:  P Isfort; T Penzkofer; A H Mahnken
Journal:  Radiologe       Date:  2012-01       Impact factor: 0.635

Review 3.  [Transarterial chemoembolization of liver metastases of colorectal carcinoma using degradable starch microspheres (Spherex): personal investigations and review of the literature].

Authors:  K Wasser; F Giebel; R Fischbach; H Tesch; P Landwehr
Journal:  Radiologe       Date:  2005-07       Impact factor: 0.635

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.